Results 81 to 90 of about 258,414 (117)

A Spanish value set for the SF-6D based on the SF-12 v1. [PDF]

Eur J Health Econ
Martínez-Pérez JE, Abellán-Perpiñán JM, Sánchez-Martínez FI, Ruiz-López JJ.   +3 more
europepmc   +1 more source

A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China. [PDF]

Adv Ther
Zhang F, Shen A, Ahmed W, Pollock RF.
europepmc   +1 more source

Digital wound monitoring with artificial intelligence to prioritise surgical wounds in cardiac surgery patients for priority or standard review: protocol for a randomised feasibility trial (WISDOM). [PDF]

BMJ Open
Tanner J, Rochon M, Harris R, Beckhelling J, Jurkiewicz J, Mason L, Bouttell J, Bolton S, Dummer J, Wilson K, Dhoonmoon L, Cariaga K.   +11 more
europepmc   +1 more source

Evolving Food Allergy Clinical Trials to Become More Patient-Centered. [PDF]

J Allergy Clin Immunol Pract
Dantzer JA, Shaker MS, Greenhawt M.
europepmc   +1 more source

Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population

Breast Cancer, 2021
The Short-Form Six-Dimension version 2 (SF-6Dv2) is the newest preference-based instrument for estimation of quality adjusted life-years (QALYs). The aim of this study is to evaluate the validity and reliability of the SF-6Dv2 in an Iranian breast cancer population.The SF-6Dv2 and FACT-B instruments were completed for 416 patients who were recruited ...
Hossein Safari, Hosein Ameri, Azin Nahvijou   +2 more
exaly   +4 more sources

Creating an SF-6Dv2 social value set for New Zealand [PDF]

Social Science & Medicine
The SF-6D health descriptive system and its second version published in 2020, the SF-6Dv2, is used worldwide for valuing health-related quality of life (HRQoL) for economic evaluation and measuring patient-reported health outcomes. In this study, a valuation tool was developed and applied to create a social value set, comprising 18,750 health state ...
Paul Hansen, Trudy Sullivan, Franz Ombler   +2 more
exaly   +4 more sources

Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China

European Journal of Health Economics
To assess and compare the measurement properties of EQ-5D-5L and SF-6Dv2 among lymphoma patients in China.A face-to-face survey of Chinese lymphoma patients was conducted at baseline (all types) and follow-up (diffuse large B-cell). EQ-5D-5L and SF-6Dv2 health utility scores (HUSs) were calculated using the respective Chinese value sets. Ceiling effect
Nan Luo, Zhuxin Mao
exaly   +5 more sources

A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L

European Journal of Health Economics
To evaluate the comparative performance of SF-6Dv2 and EQ-5D-5L in the general population of Quebec (Canada), Tehran (Iran), and Japan.Data on SF-6Dv2 and EQ-5D-5L were collected in the three countries. Descriptive differences in utility values between SF-6Dv2 and EQ-5D-5L were assessed using t-tests, as well as ceiling effects were evaluated based on ...
Thomas G. Poder, Rajabali Daroudi, Richard Norman   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Population Norms for SF-6Dv2 and EQ-5D-5L in China

Applied Health Economics and Health Policy, 2022
To derive the population norms for EQ-5D-5L and SF-6Dv2 among the Chinese general population.Data collected alongside the Chinese SF-6Dv2 valuation study conducted between June and September 2019 were used. SF-6Dv2 and EQ-5D-5L, as well as social-demographic characteristics and self-reported chronic conditions, were collected through face-to-face ...
Shitong Xie, Jing Wu, Feng Xie
exaly   +3 more sources